Diabetes technology & therapeutics · 2026
Association of Time in Tight Range with Microvascular Complications in Japanese Patients with Type 2 Diabetes Mellitus: A Multicenter Cross-Sectional Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Torimoto Keiichi, Okada Yosuke, Mita Tomoya, Tanaka Kenichi, Sato Fumiya, Katakami Naoto, Yoshii Hidenori, Nishida Keiko, Nakayamada Shingo, Ishii Ryota, Gosho Masahiko, Shimomura Iichiro, Watada Hirotaka
Аннотация
BACKGROUND: To determine the correlation between time in tight range (TITR; 70-140 mg/dL) and prevalence of microvascular complications in patients with type 2 diabetes mellitus (T2DM).
METHODS: Data of 999 patients with T2DM and negative history of cardiovascular disease were analyzed. TITR was assessed using data from a continuous glucose monitoring (CGM) system. Participants were stratified into quartiles based on TITR (Q1: ≤42.6%, Q2: >42.6 to ≤61.2%, Q3: >61.2 to ≤73.4%, Q4: >73.4%). The correlation of TITR/microvascular complications was assessed using multivariate logistic regression analysis after adjustment for potential confounders.
RESULTS: The mean TITR was 56.8 ± 22.4%, and 51.2% of participants had at least one microvascular complication. The adjusted odds ratios for any microvascular complication across increasing TITR quartiles were 1.00 (Q1 as the reference group), 0.39 (Q2; 95% confidence interval [CI]: 0.25-0.62), 0.45 (Q3; 95% CI: 0.28-0.70), and 0.30 (Q4; 95% CI: 0.19-0.47). This indicated that the prevalence of diabetic microvasculopathies was lower in higher TITR quartiles. Similar inverse trends were observed for retinopathy, nephropathy, and peripheral neuropathy. Each 10% increase in TITR was associated with a reduced risk of each type of diabetic microvasculopathy. Receiver operating characteristic curve analysis identified 54.3% as the optimal TITR cutoff value for the identification of microvascular complications.
CONCLUSIONS: Higher TITR was significantly associated with lower prevalence of microvascular complications in patients with T2DM. CGM-derived TITR is a potentially useful clinical metric for optimizing glycemic management and reducing the risk of microvascular complications.
TRIAL REGISTRATION NUMBER: UMIN000032325.
METHODS: Data of 999 patients with T2DM and negative history of cardiovascular disease were analyzed. TITR was assessed using data from a continuous glucose monitoring (CGM) system. Participants were stratified into quartiles based on TITR (Q1: ≤42.6%, Q2: >42.6 to ≤61.2%, Q3: >61.2 to ≤73.4%, Q4: >73.4%). The correlation of TITR/microvascular complications was assessed using multivariate logistic regression analysis after adjustment for potential confounders.
RESULTS: The mean TITR was 56.8 ± 22.4%, and 51.2% of participants had at least one microvascular complication. The adjusted odds ratios for any microvascular complication across increasing TITR quartiles were 1.00 (Q1 as the reference group), 0.39 (Q2; 95% confidence interval [CI]: 0.25-0.62), 0.45 (Q3; 95% CI: 0.28-0.70), and 0.30 (Q4; 95% CI: 0.19-0.47). This indicated that the prevalence of diabetic microvasculopathies was lower in higher TITR quartiles. Similar inverse trends were observed for retinopathy, nephropathy, and peripheral neuropathy. Each 10% increase in TITR was associated with a reduced risk of each type of diabetic microvasculopathy. Receiver operating characteristic curve analysis identified 54.3% as the optimal TITR cutoff value for the identification of microvascular complications.
CONCLUSIONS: Higher TITR was significantly associated with lower prevalence of microvascular complications in patients with T2DM. CGM-derived TITR is a potentially useful clinical metric for optimizing glycemic management and reducing the risk of microvascular complications.
TRIAL REGISTRATION NUMBER: UMIN000032325.